HilleVax, Inc.

Developing bivalent VLP vaccine against Norovirus

Hillevax was launched in early 2021 by Tachi Yamada, Rob Hershberg, David Socks and Aditya Kohli and further supported by Frazier Healthcare Partners to develop a vaccine against Norovirus. Norovirus causes significant mortality, morbidity, and economic burden and is the leading cause of acute gastroenteritis in US and worldwide. The company has in-licensed TAK-214 from Takeda Pharmaceuticals, a Phase IIb-ready bivalent VLP vaccine for major genotypes GI.I (Norwalk) and consensus GII.4 which comprise the majority of norovirus infections worldwide.